Bayer (BAYA) AI Stock Analysis

Bayer

(Frankfurt:BAYA)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Crop Science growth and marginsCrop Science is showing both revenue growth and strong profitability, suggesting improved mix and operating execution rather than growth purchased solely through volume. A 31% EBITDA margin provides a durable earnings base and supports reinvestment across Bayer’s agricultural portfolio.

Negative Factors

Persistent net lossesPersistent net losses show that Bayer’s strong gross margins are not yet translating into sustainable bottom-line profitability. Continued earnings weakness can constrain internal investment, reduce resilience during operating setbacks, and make the company more dependent on portfolio and cost improvements.

Bayer (BAYA) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 54.98B
Dividend Yield: 0.21%
Average Volume (3M): 408
Price to Earnings (P/E): -28.7
Beta (1Y): 1.13
Revenue Growth: -1.73%
EPS Growth: 49.15%
Country: Germany
Employees: 88,078
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - General

Bayer Business Overview & Revenue Model

Company Description

Bayer Aktiengesellschaft, commonly known as Bayer AG, functions as a prominent global life sciences company through its various subsidiaries. Its extensive operations are strategically segmented into Pharmaceuticals, Consumer Health, and Crop Science...

Bayer Earnings Call Summary

Earnings Call Date:Aug 03, 2026(Q2-2026)|% Change Since:6.72%|Next Earnings Date:Nov 02, 2026

Earnings Call SentimentPositive

The call presented multiple clear operational and strategic positives — steady group sales (+3%), EBITDA improvement (+7%), Crop Science margin expansion to 31%, strong growth in several Pharma assets (Nubeqa and Kerendia +66%), successful capital transactions (EUR 3bn Apollo investment and USD 5bn bond issuance) and a favorable U.S. Supreme Court ruling that materially strengthens litigation containment. Offsetting these strengths are meaningful near-term financial drains: negative free cash flow (‑EUR 2.7bn) driven by EUR 2.5bn in litigation payouts, elevated net debt in the near term (EUR 33.6bn), a 17% drop in Q2 core EPS due to normalization, Eylea sales down 27%, and continued legal and external-market risks. On balance, the highlights materially outweigh the lowlights given improving profitability, strategic progress, and decisive financing actions that reduce medium-term balance-sheet risk.

Positive Updates

Group Sales Growth

Net sales grew 3% year-over-year to EUR 24.3 billion in the first half (Q2 sales +2% to EUR 10.9 billion), showing the group is pacing to meet full-year guidance.

Negative Updates

Negative Free Cash Flow and Litigation Payouts

Free cash flow was negative EUR 2.7 billion in H1 versus minus EUR 1.4 billion a year earlier, driven by material litigation-related payouts of about EUR 2.5 billion in the period.

Company Guidance

Bayer reiterated its full‑year 2026 outlook at constant currencies after a H1 showing that it says keeps the group on track: net sales H1 EUR 24.3bn (+3% cc) and Q2 EUR 10.9bn (+2% cc); EBITDA before special items H1 EUR 6.6bn (+7%) and Q2 EUR 2.1bn (+2%); core EPS H1 EUR 3.66 (+3%) with Q2 core EPS EUR 0.95 (‑17% YoY); H1 free cash flow was negative EUR 2.7bn (vs ‑EUR 1.4bn LY), driven by ~EUR 2.5bn of litigation‑related payouts. By division: Crop Science sales +5.5% (EBITDA margin 31%), Pharma sales flat (Nubeqa+Kerendia +66%, Eylea ‑27%, Pharma EBITDA margin 26%), and Consumer Health +3.5% (EBITDA margin trailing prior year). Net financial debt stood at EUR 33.6bn (slightly up YoY; +EUR 1.1bn vs Q1) but management now expects EUR 29–30bn after a EUR 3bn Apollo minority equity investment (to close H2) and notes a successful USD 5bn bond placement; FX updated to June month‑end rates slightly lowers the headwind to sales and core EPS versus the prior estimate.

Bayer Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:BAYA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PFE	74Outperform	$173.95B	40.33	4.89%	5.64%	-0.21%	-59.71%
NVS	72Outperform	$296.91B	31.19	24.24%	2.95%	1.64%	-28.72%
SNY	71Outperform	$106.82B	24.39	5.52%	5.46%	23.68%	-30.90%
JNJ	70Outperform	$657.68B	41.42	19.55%	1.93%	7.81%	-35.95%
GSK	67Neutral	$99.56B	17.18	24.64%	3.67%	6.93%	-18.14%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:BAYA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:BAYA	Bayer AG	12.70	6.36	100.44%
GSK	GlaxoSmithKline	49.51	4.27	9.44%
JNJ	Johnson & Johnson	273.20	90.46	49.50%
NVS	Novartis AG	160.79	38.18	31.14%
PFE	Pfizer Inc	30.52	7.81	34.41%
SNY	Sanofi SA	44.34	-2.89	-6.11%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Bayer AI Stock Analysis